ArticleRenal failure2026
Proactive iron supplementation alone in patients on chronic hemodialysis is not sufficient.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dialysis patients often become iron-deficient because of many factors, including poor iron absorption from the gut, blood loss during dialysis, frequent blood draws, phosphate binders, and the use of erythropoietin. Oral supplementation is ineffective because of elevated hepcidin levels and low levels of iron-absorbing factors in the duodenal mucosa. Intravenous iron supplementation can be given in two forms: one is to replace iron when the iron content or total iron binding capacity saturation (FeSat) is too low, that is, a reactive dosing (RE); or by administering iron on a schedule of weekly proactive dosing (PRO), as recommended by guidelines. We investigated whether PRO alone is sufficient, as our hospital-based dialysis unit used a PRO schedule according to our current protocol. The data of 102 patients receiving a mean 107.7 ± 65.9 mg/week of intravenous iron (sodium ferric gluconate complex) were analyzed. Fifty-four of the 91 patients with complete datasets had an FeSat 25 (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.